Physician profile
Reena S Patel
NPI 1831406412
$8,314.86
in general payments reported to CMS, 2019-2025
21 companies · $307 in 2025
The $307 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,111 · 2020: $166 · 2021: $473 · 2022: $2,106 · 2023: $1,017 · 2024: $2,136 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,972 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $850 · Consulting Fee: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.59 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850.00 |
| Consulting Fee | $637.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,632.60 | 2019-2024 | Exalt Model D, Axios, Resolution 360 Clip |
| Abbvie INC. | $1,674.17 | 2019-2025 | |
| Apollo Endosurgery US INC | $832.90 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $148.08 | 2021-2025 | Tremfya |
| Ardelyx, INC. | $125.17 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $121.38 | 2019 | |
| Medtronic USA, INC. | $99.93 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $97.85 | 2022 | |
| Intuitive Surgical, INC. | $91.21 | 2019 | |
| Janssen Biotech, INC. | $89.60 | 2024 | Stelara |
| Phathom Pharmaceuticals, INC. | $72.03 | 2024-2025 | Voquezna |
| Genzyme Corporation | $68.97 | 2025 | |
| Erbe USA INC | $60.00 | 2023 | Erbe Vio3 |
| Gilead Sciences, INC. | $37.03 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.05 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $33.48 | 2025 | Andembry |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.24 | 2019 | |
| Beigene USA, INC. | $20.46 | 2024 | Brukinsa |
| Celltrion USA INC. | $18.91 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $17.49 | 2019 | |
| Daiichi Sankyo INC. | $13.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.